Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 18/20 | 0.42 |
| ▸ | TUBB | P07437 | 18/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 18/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 18/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 18/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 18/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 18/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 18/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 18/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 18/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 18/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 18/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 18/20 | 0.42 |
| ▸ | TUBB2B | Q9BVA1 | 18/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 18/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25478448 | 0.85 | NPSR1 (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL725347 | 0.83 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL724076 | 0.81 | CYP1A2 (0.51) | — | |
| SCHEMBL724565 | 0.78 | MAPT (0.44) | TUBB1PDE2A | |
| SCHEMBL25479020 | 0.77 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL724190 | 0.74 | ALDH1A1 (0.54) | PDE2A | |
| SCHEMBL1683758 | 0.74 | CNR2 (0.52) | — | |
| SCHEMBL3469479 | 0.74 | EGFR (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL724015 | 0.74 | CNR2 (0.55) | — | |
| SCHEMBL17449550 | 0.74 | TUBB4A (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
| US-9029408-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | TUBB4A 237/4885TUBB 461/4885TUBA3C 625/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | TUBB4A 237/4885TUBB 461/4885TUBA3C 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.